Harvard University: “Cannabis Eliminates Completely Pancreatic Cancer”

March 5, 2020

The scientists of the Dana Farber Institute whose mission is to study cancer at Harvard University managed to completely eliminate malignant tumors in rats with pancreatic cancer thanks to a cannabis extract.

Pancreatic cancer is today one of the deadliest that exists and has a life expectancy of 5 years in just 9% of the population.

This has been the conclusion of the researchers who have just published the result in the Frontiers of Oncology.

In it, the researchers tested the effects of flavonoids, a compound derived from cannabis, on pancreatic cancer cells in mice.

The result surprised the researchers.

“We hope it will show some inhibition of tumor growth, but it was not surprising that it also inhibited tumor progression in other parts of the body. We really had to perform some additional measurements to see if this was really true,” said lead researcher Dr. Wilfred Ngwa.

The researchers’ biggest surprise was that the research exceeded traditional radiotherapy. The team now investigates whether by 2020 the treatment could be tested in humans.

Flavonoids are compounds that are practically in all plants, fruits and vegetables since they are the ones who give color to them.

The novelty of this research is to know about the administration of cannabis-derived flavonoids and their relationship directly with cell and metastatic destruction.

In addition, this finding could translate into an increase in the life expectancy of this type of patients since pancreatic cancer is often diagnosed in advanced stages and it seems that with this type of cannabis flavonoid approach they could be destroyed these cancer cells.

“If it translates into clinical success, this will have a major impact on the treatment of pancreatic cancer,” the researcher concluded.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663976/

Photo by National Cancer Institute


Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.



CanPharma GmbH
Wiesbadener Str. 29,
16515 Oranienburg, Germany



Rosenthaler Str. 34
10178 Berlin

Gran de Gràcia 15, 1-1
08012 Barcelona